There are around 160 to 170 anti-aging companies focused on creating solutions! That’s the good news.
The bad news? About two dozen of them are publicly traded and almost all have declined significantly in value since their IPO. The rest remain privately held. The historical track record of investing in anti-aging companies is quite poor!
That said, with the vastly increased technical capabilities of modern science, there is tremendous potential going forward. Will some of these emerging companies overcome the aging processes and enable greater healthspan and longevity for humanity? Let’s take a look at some of the more notable ones.
It turns out that the super-wealthy are interested in owning more than just the top media companies in the world. As they begin to see signs of their mortality, they fund new anti-aging companies as well. As a few examples:
In 2013, Google founders Sergey Brin and Larry Page created Calico Labs (@calico). Craig Venter and Peter Diamandis created Human Longevity.
In 2016, British billionaire Jim Mellon launched Juvenescence and AgeX Therapeutics (@agexthera). Jeff Bezos and Peter Thiel funded Unity Biotechnology.
In 2017, David Sinclair and others started Life Biosciences, funded by wealthy individuals including WeWork’s Adam Neumann.
Each of these ventures struggled, both financially and in retaining their top scientists. Calico has no pipeline of candidate solutions. Human Longevity’s founders departed and the company evolved into a very good, but small scale full body testing medical center. Juvenescence has tried to IPO for several years. Many of their acquisitions have failed to make breakthroughs. AgeX is publicly traded below $1/share, underfunded and not making much progress. Unity’s lead clinical trial failed. Life Biosciences has yet to launch a clinical trial, although they raised $82MM in 1H, 2022 with plans for a trial in 2H, 2023. On the positive side, they found a way to restore vision in old mice.
Funding from the super-wealthy has not yet been a good indicator for human success. However, this will not stop the rich and powerful from continuing to try.
From 2021-2022, there is another cycle of new anti-aging companies funded by the super wealthy. Most are focused on rejuvenation via Induced Tissue Response (#iTR). Once again they are paying top dollar to acquire prestigious scientists. These anti-aging companies include:
Will the high-priced all-star teams succeed or will smaller funded, but established and practical competitors beat them to market? Here are a few intriguing contenders, among many.
Hopefully, many of these companies become successful. However, there is no single panacea for aging. Anti-aging medical solutions require addressing many of the 24 Key Health Factors for 2024. Individual drugs and medical treatments cannot address all of them as comprehensive solutions are required. A deep level of collaboration across multiple companies and multiple modalities will be needed. It will be interesting to see which companies emerge to take this role once further progress is made.
Thanks for taking time to read this article and care about your health. As your reward, we leave you with this Will Rogers line, “We could certainly slow the aging process down if it had to work its way through Congress.”
What would you like to know about the future of health? In 2015, Jeremy Jacobs,…
Ubiquinol is a derivative of Coenzyme Q10 (CoQ10) that is fully reduced and saturated with…
The benefits of meditation, an ancient practice rooted in mindfulness and self-awareness, have become well-known…
This article covers optimal breathing techniques for sleeping, sprinting, distance running, swimming, and singing. Breathing…
There is a wealth health connection. In most cases, having wealth increases health and longevity.…
Biohackers use their own bodies to experiment on making small, incremental diet or lifestyle changes…